Novel usage of human antalzyme in the process for preparing ophthalmopathy treating medicine

A human lysozyme and drug technology, which is applied in the directions of antibacterial drugs, drug combinations, sensory diseases, etc., to achieve the effects of safety, no toxic side effects, convenient use and simple preparation process

Active Publication Date: 2005-03-16
张华
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although new antibiotics are constantly being developed and put into use, within a short period of time, new drug-resistant strains have emerged

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0215] Recombinant human lysozyme is based on the preparation of 200 ml medium, with 6 ml phosphoric acid, 3 g magnesium sulfate, 4 g potassium sulfate, 1 g potassium hydroxide, 1.5 g calcium sulfate, add distilled water to 200 ml, after autoclaving Glycerol tube seeds are inoculated, the rotation speed of the shaker is 250 revolutions per minute, the cultivation temperature is 20-35° C., and the cultivation is carried out on a constant temperature bed for 36-48 hours. The seed tank culture is carried out, and finally the production tank culture is carried out. Extract and purify the culture medium that has been fermented and expressed, freeze-dry the extracted and purified protein concentrate, measure the protein and store it for activity. In a pharmaceutical factory that meets the requirements of GMP, according to the pharmaceutical regulations, the recombinant human lysozyme with a purity of 95% was prepared to 30000U / mL, and the phosphate buffer was 10-20mM (pH6.5-7.5) 80%...

Embodiment 2

[0217] According to the preparation method described in Example 1, in a pharmaceutical factory meeting the requirements of GMP, 1,000,000 U / mL of recombinant human lysozyme with a purity of 95% was produced according to pharmaceutical regulations, and 10-20 mM phosphate buffer (pH6.5- 7.5) Mix 80%, 5-25% propylene glycol, and 5 / 10,000 Tween 80 at room temperature to make eye drops.

Embodiment 3

[0219] According to the preparation method described in Example 1, in a pharmaceutical factory meeting the GMP requirements, 2,000,000 U / mL of recombinant human lysozyme with a purity of 95% was produced according to pharmaceutical regulations, and 10-20 mM phosphate buffer (pH6.5- 7.5) Mix 80%, 5-25% propylene glycol, and 5 / 10,000 Tween 80 at room temperature to make eye drops.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the novel use of human lysozyme, in particular the use of human lysozyme in pharmaceutical industry, specifically the use of human lisozima in preparing ophthalmocace treating medicine, such as epidemic conjunctivitis, opthalmitis, ceratitis, corneal ulcer diseases caused by bacterium, Chlamydia, viruses and drug resistant medicines. The gene recombination lysozyme has rich source, the eye drops prepared thereby are easy to use.

Description

Technical field: [0001] The present invention relates to a new application of human lysozyme, especially a new application in the field of pharmacy. Background technique: [0002] At present, various pink eye diseases, ophthalmia, keratitis, corneal ulcers and other diseases caused by bacteria, viruses, etc. are very common. Antibiotic eye drops are generally used for treatment. However, in the 21st century today, the development of drug-resistant bacteria is shocking. From The development history of bacterial resistance can be seen that after the emergence of a new antibiotic, a group of resistant strains appeared. It generally takes about 10 years to develop a new antibiotic, but it only takes 2 years to produce a generation of drug-resistant bacteria. The development speed of antibiotics is far behind the development speed of drug-resistant bacteria. The more antibiotics you use, the more ways bacteria can mutate to avoid them. Due to the misuse of antibiotics, a consid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61P27/02A61P31/04A61P31/12
CPCY02A50/30
Inventor 张华
Owner 张华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap